These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11741223)

  • 41. Ultrasound has synergistic effects in vitro with tirofiban and heparin for thrombus dissolution.
    Birnbaum Y; Atar S; Luo H; Nagai T; Siegel RJ
    Thromb Res; 1999 Dec; 96(6):451-8. PubMed ID: 10632468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK; Schleuning WD
    Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual effect of synthetic plasmin substrates on plasminogen activation.
    Kolev K; Owen WG; Machovich R
    Biochim Biophys Acta; 1995 Mar; 1247(2):239-45. PubMed ID: 7696314
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delivery system for targeted thrombolysis without the risk of hemorrhage.
    Byun Y; Yang VC
    ASAIO J; 1998; 44(5):M638-41. PubMed ID: 9804513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The potential mechanism for the effect of heparin on tissue plasminogen activator-mediated plasminogen activation.
    Liang JF; Li Y; Yang VC
    Thromb Res; 2000 Mar; 97(5):349-58. PubMed ID: 10709911
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.
    Absar S; Nahar K; Kwon YM; Ahsan F
    Pharm Res; 2013 Jun; 30(6):1663-76. PubMed ID: 23468049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.
    Leaker MT; Brooker LA; Mitchell LG; Weitz JI; Superina R; Andrew ME
    Transplantation; 1995 Jul; 60(2):144-7. PubMed ID: 7624956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator.
    Dansdill D; Halandras PM; Beverly J; Jeske W; Hoppensteadt D; Emanuele M; Fareed J; Cho JS
    J Vasc Surg; 2018 Jan; 67(1):294-299. PubMed ID: 27939143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions.
    Chmielewska J; Rånby M; Wiman B
    Biochem J; 1988 Apr; 251(2):327-32. PubMed ID: 3135797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
    Reed GL; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
    [No Abstract]   [Full Text] [Related]  

  • 51. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The activation of type 1 and type 2 plasminogen by type I and type II tissue plasminogen activator.
    Mori K; Dwek RA; Downing AK; Opdenakker G; Rudd PM
    J Biol Chem; 1995 Feb; 270(7):3261-7. PubMed ID: 7852411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators.
    Angles-Cano E
    Anal Biochem; 1986 Mar; 153(2):201-10. PubMed ID: 3085533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
    Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasminogen activator-anti-human fibrinogen conjugate.
    Sevilla CL; Mahle NH; Boylan CM; Callewaert DM
    Biochem Biophys Res Commun; 1985 Jul; 130(1):91-6. PubMed ID: 3161501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clearance of a novel recombinant tissue plasminogen activator in rabbits.
    Fu KP; Lee S; Hetzel N; Fenichel R; Hum HW; Speth J; Kalyan N; Hung PP
    Thromb Res; 1988 Jun; 50(5):679-85. PubMed ID: 3137685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle.
    Chen JP; Yang PC; Ma YH; Tu SJ; Lu YJ
    Int J Nanomedicine; 2012; 7():5137-49. PubMed ID: 23055726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The potency of tissue-type plasminogen activator (TPA) determined with chromogen and clot-lysis assays.
    Christodoulides M; Boucher DW
    Biologicals; 1990 Apr; 18(2):103-11. PubMed ID: 2115789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced control of bioactivity of tissue plasminogen activator (tPA) through domain-directed enzymatic oxidation of terminal galactose.
    Mahdi WA; Absar MS; Choi S; Yang VC; Kwon YM
    Bioimpacts; 2022; 12(6):479-486. PubMed ID: 36644546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.